Basic mechanisms of urgency: Roles and benefits of pharmacotherapy

World Journal of Urology

Volumn 27, Issue 6, 2009, Pages 705-709

  Michel, Martin Christian ^a   Chapple, Christopher R ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bladder sensation; Urge to void; Urgency

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; BLADDER; HUMAN; INNERVATION; MICTURITION DISORDER; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMANS; MUSCARINIC ANTAGONISTS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION DISORDERS;

EID: 71249128718     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0446-5     Document Type: Article

References (64)

1. P Abrams L Cardozo M Fall, et al. 2002 The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 167 178 10.1002/nau.10052 (Pubitemid 34195211)
2. MC Michel CR Chapple 2009 Basic mechanisms of urgency: basic and clinical evidence Eur Urol 10.1016/j.eururo.2009.05.028
3. S Oliver C Fowler A Mundy, et al. 2003 Measuring the sensation of urge and bladder filling during cystometry in urge incontinence and the effect of neuromodulation Neurourol Urodyn 22 7 16 10.1002/nau.10082 (Pubitemid 36008975)
4. L Lowenstein MP Fitzgerald K Kenton, et al. 2008 Validation of a real-time urodynamic measure of urinary sensation Am J Obstet Gynecol 198 661.e1 661.e5 10.1016/j.ajog.2008.02.023
5. J-J Wyndaele TD van Meel S de Wachter 2004 Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J Urol 172 1915 1918 10.1097/01.ju.0000142429.59753.5c (Pubitemid 39363089)
6. J Malone-Lee DJE Henshaw K Cummings 2003 Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response BJU Int 92 415 417 10.1046/j.1464-410X.2003.04351.x (Pubitemid 37100520)
7. Rovner E, Payne C, Yalla S et al (2005) Response to fesoterodine in overactive bladder (OAB) patients is independent of the uryodynamic finding of detrusor overactivity. https://www.icsoffice.org/publications/2005/PDF/0147.PDF
8. G Matharu MMK Donaldson CW McGrother, et al. 2005 Relationship between urinary symptoms reported in a postal questionnaire and urodynamic diagnosis Neurourol Urodyn 24 100 105 10.1002/nau.20093 (Pubitemid 40229423)
9. H Hashim P Abrams 2006 Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175 191 195 10.1016/S0022-5347(05)00067-4 (Pubitemid 41797136)
10. BT Haylen N Chetty V Logan, et al. 2007 Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity? Int Urogynecol J 18 123 128 10.1007/s00192-006-0165-z
11. S de Wachter TD van Meel J-J Wyndaele 2008 Can a faked cystometry deceive patients in their perception of filling sensations? A study on the reliability of spontaneous reported cystometric filling sensations in patients with non-neurogenic lower urinary tract dysfunction Neurourol Urodyn 27 395 398 10.1002/nau.20523 (Pubitemid 351991202)
12. Morrison J, Birder LA, Craggs M et al (2006) Neural control. Plymbridge Distributors Ltd, Plymouth, pp 363-422
13. J Morrison 1999 The activation of bladder wall afferent nerves Exp Physiol 84 131 136
14. KS Lips J Wunsch S Sarghooni, et al. 2007 Acetylcholine and molecular components of its synthesis and release machinery in the urothelium Eur Urol 51 1042 1053 10.1016/j.eururo.2006.10.028 (Pubitemid 46281424)
15. M Yoshida K Masunaga Y Satoji, et al. 2008 Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance J Pharmacol Sci 106 193 198 10.1254/jphs.FM0070115
16. N Yoshimura Y Kaiho M Miyazato, et al. 2008 Therapeutic targets for lower urinary tract dysfunction Naunyn Schmiedebergs Arch Pharmacol 377 437 448 10.1007/s00210-007-0209-z
17. MP Fitzgerald KS Kenton L Brubaker 2005 Localization of the urge to void in patients with painful bladder syndrome Neurourol Urodyn 24 633 637 10.1002/nau.20177 (Pubitemid 41572775)
18. P Bulmer P Abrams 2004 The unstable detrusor Urol Int 72 1 12 10.1159/000075265 (Pubitemid 38134882)
19. BS Athwal KJ Berkley I Hussain, et al. 2001 Brain responses to changes in bladder volume and urge to void in healthy men Brain 124 369 377 10.1093/brain/124.2.369
20. D Griffiths SD Tadic 2008 Bladder control, urgency, and urge incontinence: evidence from functional brain imaging Neurourol Urodyn 27 466 474 10.1002/nau.20549
21. K-E Andersson 2004 New pharmacological targets for the treatment of the overactive bladder: an update Urology 63 Suppl 3A 32 41 10.1016/j.urology.2003. 10.005 (Pubitemid 38317360)
22. M Kono Y Nakamura Y Ishiura, et al. 2006 Central muscarinic receptor subtypes regulating voiding in rats J Urol 175 353 357 10.1016/S0022-5347(05) 00004-2 (Pubitemid 41797202)
23. A Cucchi S Quaglini S Siracusano, et al. 2006 Urgency degree and bladder contraction velocity: sequential changes in women with idiopathic detrusor overactivity Neurourol Urodyn 25 123 127 10.1002/nau.20217
24. A Cucchi S Quaglini B Rovereto 2007 Relationships between micturition urgency and involuntary voiding dynamics in men with urinary incontinence from idiopathic detrusor overactivity J Urol 178 563 567 10.1016/j.juro.2007.03.122 (Pubitemid 47030501)
25. T Schneider C Fetscher S Krege, et al. 2004 Signal transduction underlying carbachol-induced contraction of human urinary bladder J Pharmacol Exp Ther 309 1148 1153 10.1124/jpet.103.063735 (Pubitemid 38669703)
26. EP Frazier SLM Peters AS Braverman, et al. 2008 Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors Naunyn Schmiedebergs Arch Pharmacol 377 449 462 10.1007/s00210-007-0208-0
27. DE Rapp MB Lyon GT Bales, et al. 2005 A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction Eur Urol 48 303 308 10.1016/j.eururo.2005.04.019 (Pubitemid 40957109)
28. GN Sibley 1984 A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit J Physiol (Lond) 354 431 443
29. CH Fry C Wu AR Mundy 1999 Bladder instability and detrusor smooth muscle function Exp Physiol 84 161 169
30. CH Fry D Skennerton D Wood, et al. 2002 The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders Urology 59 Suppl 5A 3 12 10.1016/S0090-4295(01)01632-6 (Pubitemid 34462252)
31. SLM Peters M Schmidt MC Michel 2006 Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 27 492 497 10.1016/j.tips.2006.07.002 (Pubitemid 44233691)
32. CH Fry 2004 Experimental models to study the physiology, pathophysiology and pharmacology of the lower urinary tract J Pharmacol Toxicol Methods 49 201 210 10.1016/j.vascn.2004.03.002 (Pubitemid 38686658)
33. BL Coolsaet WA van Duyl P van Os-Bossagh, et al. 1993 New concepts in relation to urge and detrusor overactivity Neurourol Urodyn 12 463 471 10.1002/nau.1930120504 (Pubitemid 23306360)
34. MJ Drake IJ Harvey JI Gillespie, et al. 2005 Localized contractions in the normal human bladder and in urinary urgency BJU Int 95 1002 1005 10.1111/j.1464-410X.2005.05455.x (Pubitemid 40655695)
35. JE Greenland AF Brading 2001 The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs J Urol 165 245 248 10.1097/00005392-200101000-00072
36. MC Michel MM Barendrecht 2008 Physiological and pathological regulation of the autonomic control of urinary bladder contractility Pharmacol Ther 117 297 312 10.1016/j.pharmthera.2007.12.001
37. PH Abrams DJ Farrar RT Turner-Warwick, et al. 1979 The results of prostatectomy: a symptomatic and urodynamic analysis in 152 patients J Urol 121 640 642
38. CR Chapple V Khullar Z Gabriel, et al. 2008 The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 543 562 10.1016/j.eururo.2008.06.047
39. G Novara A Galfano S Secco, et al. 2008 A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder Eur Urol 54 740 764 10.1016/j.eururo.2008.06.080
40. MC Michel M Oelke M Goepel, et al. 2007 Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients Neurourol Urodyn 26 190 195 10.1002/nau.20367 (Pubitemid 46595716)
41. JS Starkman RR Dmochowski 2008 Urgency assessment in the evaluation of overactive bladder (OAB) Neurourol Urodyn 27 13 21 10.1002/nau.20472
42. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder Eur Urol 45 420 429 10.1016/j.eururo.2004.01.008 (Pubitemid 38376197)
43. 3-selective receptor antagonist BJU Int 95 580 586 10.1111/j.1464-410X.2005.05343.x (Pubitemid 40311477)
44. V Khullar ES Rovner R Dmochowski, et al. 2008 Fesoterodine dose response in subjects with overactive bladder syndrome Urology 71 839 843 10.1016/j.urology.2007.12.017
45. C Chapple P van Kerrebroeck A Tubaro, et al. 2007 Clinical efficacy, safety and tolerability of once-daily fesoterodine in subjects with overactive bladder Eur Urol 52 1204 1212 10.1016/j.eururo.2007.07.009
46. VW Nitti R Dmochowski PK Sand, et al. 2007 Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome J Urol 178 2488 2494 10.1016/j.juro.2007.08.033 (Pubitemid 350052177)
47. O Yamaguchi E Marui H Kakizaki, et al. 2007 Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder BJU Int 100 579 587 10.1111/j.1464-410X.2007.07031.x (Pubitemid 47205477)
48. CR Chapple P Arano JLHR Bosch, et al. 2004 Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study BJU Int 93 71 77 10.1111/j.1464-410X.2004.04561.x (Pubitemid 38112970)
49. CR Chapple T Rechberger S Al-Shukri, et al. 2004 Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 303 310 10.1111/j.1464-410X.2004.04606.x (Pubitemid 38253574)
50. L Cardozo M Lisec R Millard, et al. 2004 Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder J Urol 172 1919 1924 10.1097/01.ju.0000140729.07840.16 (Pubitemid 39363090)
51. SA Kaplan CG Roehrborn R Dmochowski, et al. 2006 Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia Urology 68 328 332 10.1016/j.urology.2006.03.006 (Pubitemid 44175507)
52. V Khullar S Hill K-U Laval, et al. 2004 Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial Urology 64 269 275 10.1016/j.urology.2004.02.029 (Pubitemid 39092452)
53. N Zinner M Gittelman R Harris, et al. 2004 Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial J Urol 171 2311 2315 10.1097/01.ju.0000127742.73136.0c (Pubitemid 38625460)
54. R Freeman S Hill R Millard, et al. 2003 Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine Obstet Gynecol 102 605 611 10.1016/S0029-7844(03)00623-9 (Pubitemid 37311230)
55. L Cardozo A Dixon 2005 Increased warning time with darifenacin: a new concept in the management of urinary urgency J Urol 173 1214 1218 10.1097/01.ju.0000155798.78911.57 (Pubitemid 40380539)
56. N Zinner M Harnett L Sabounjian, et al. 2005 The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder J Urol 173 1639 1643 10.1097/01.ju.0000154692.73129.d8 (Pubitemid 40524794)
57. R Dmochowski P Abrams D Marschall-Kehrel, et al. 2007 Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder Eur Urol 51 1054 1064 10.1016/j.eururo.2006.10.005 (Pubitemid 46281419)
58. VW Nitti R Dmochowski RA Appell, et al. 2006 Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia BJU Int 97 1262 1266 10.1111/j.1464-410X.2006.06146.x (Pubitemid 43907334)
59. MC Michel JJMCH de la Rosette M Piro, et al. 2005 Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder Eur Urol 48 110 115 10.1016/j.eururo.2004.11.012 (Pubitemid 40835603)
60. H Madersbacher M Halaska R Voigt, et al. 1999 A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence BJU Int 84 646 651 10.1046/j.1464-410x.1999.00251.x (Pubitemid 29457181)
61. CR Chapple O Yamaguchi A Ridder, et al. 2008 Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder Eur Urol Suppl 7 239
62. A Avelino F Cruz 2006 TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications Naunyn Schmiedebergs Arch Pharmacol 373 287 299 10.1007/s00210-006-0073-2 (Pubitemid 43999780)
63. ®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review Eur Urol 53 275 287 10.1016/j.eururo.2007.10.013 (Pubitemid 350296587)
64. K-E Andersson 2007 LUTS treatment: future treatment options Neurourol Urodyn 26 934 947 10.1002/nau.20500 (Pubitemid 47548231)